BofA lowered the firm's price target on Idexx Laboratories to $660 from $790 and keeps a Neutral rating on the shares. The firm sees today's Q1 beat as "demonstrating solid execution in tough markets," but is left with questions on both macro durability and the pace of inVue placements through the balance of the year given the still-challenging macro backdrop and Q1 inVue placements coming in a bit lighter than expected, the analyst tells investors.
